SRR934720
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 147.1090670170828
- age_years
- 34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.512
- TNFA_SIGNALING_VIA_NFKB+0.464
- INFLAMMATORY_RESPONSE+0.426
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.417
- TGF_BETA_SIGNALING+0.417
- HEDGEHOG_SIGNALING+0.416
- KRAS_SIGNALING_UP+0.406
- INTERFERON_GAMMA_RESPONSE+0.334
- ANGIOGENESIS+0.325
- COMPLEMENT+0.323
Top 10 suppressed
- E2F_TARGETS-0.457
- MYC_TARGETS_V1-0.430
- DNA_REPAIR-0.408
- MYC_TARGETS_V2-0.401
- G2M_CHECKPOINT-0.304
- UNFOLDED_PROTEIN_RESPONSE-0.174
- OXIDATIVE_PHOSPHORYLATION-0.132
- PEROXISOME-0.116
- GLYCOLYSIS-0.051
- ADIPOGENESIS-0.033
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.933 |
| 2 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.900 |
| 3 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.900 |
| 4 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.898 |
| 5 | SRR6013602 | — | cohortMD2 | 0.898 |
| 6 | SRR15069612 | — | — | 0.890 |
| 7 | TCGA-AC-A2B8-01A-11R-A17B-07 | — | A | 0.887 |
| 8 | BS_52426AMF | low-grade glioma | — | 0.887 |
| 9 | MDT-AP-2111 | Med | Medulloblastoma | 0.886 |
| 10 | SRR4296080 | — | cohortA1 | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.512 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.464 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.426 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.417 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.417 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.416 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.406 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.334 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.325 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.323 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.321 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.319 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.308 | Inavolisib | — uncovered |
| APOPTOSIS | 0.305 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.296 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.294 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.279 | Idelalisib | — uncovered |
| HYPOXIA | 0.278 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.274 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.259 | Inavolisib | — uncovered |